Movement Alert｜SELLAS Life Sciences Group Inc. Falls 8.19% in Pre-Market Trading, Trading at $10.7

Market Focus

Sep 14

On September 14, SELLAS Life Sciences Group Inc. fell 8.19% in pre-market trading, trading at $10.70 USD/share, with turnover of $438,600. The stock had already declined 14.42% in the prior trading session, extending a sharp short-term downtrend.

Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, individual stock performance was mixed. Among major names, Amgen up 1.08%, AbbVie up 0.61%, Gilead Sciences up 0.41%, Vertex Pharmaceuticals down 0.06%, Moderna down 0.78%.

SELLAS Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidates include galinpepimut-S (GPS), targeting acute myeloid leukemia in a Phase 3 clinical trial, and SLS009, a highly selective CDK9 inhibitor currently in Phase 2 trials.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/1113865065"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113865065\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113865065?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 17:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113865065","market":"hk","top_or_hot":-1,"title":"Movement Alert｜SELLAS Life Sciences Group Inc. Falls 8.19% in Pre-Market Trading, Trading at $10.7","media":"Market Focus","content":"<p><p>On September 14, SELLAS Life Sciences Group Inc. fell 8.19% in pre-market trading, trading at $10.70 USD/share, with turnover of $438,600. The stock had already declined 14.42% in the prior trading session, extending a sharp short-term downtrend.</p><p>Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, individual stock performance was mixed. Among major names, Amgen up 1.08%, AbbVie up 0.61%, Gilead Sciences up 0.41%, Vertex Pharmaceuticals down 0.06%, Moderna down 0.78%.</p><p>SELLAS Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidates include galinpepimut-S (GPS), targeting acute myeloid leukemia in a Phase 3 clinical trial, and SLS009, a highly selective CDK9 inhibitor currently in Phase 2 trials.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SELLAS Life Sciences Group Inc. Falls 8.19% in Pre-Market Trading, Trading at $10.7</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SELLAS Life Sciences Group Inc. Falls 8.19% in Pre-Market Trading, Trading at $10.7\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-14 17:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 14, SELLAS Life Sciences Group Inc. fell 8.19% in pre-market trading, trading at $10.70 USD/share, with turnover of $438,600. The stock had already declined 14.42% in the prior trading session, extending a sharp short-term downtrend.</p><p>Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, individual stock performance was mixed. Among major names, Amgen up 1.08%, AbbVie up 0.61%, Gilead Sciences up 0.41%, Vertex Pharmaceuticals down 0.06%, Moderna down 0.78%.</p><p>SELLAS Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidates include galinpepimut-S (GPS), targeting acute myeloid leukemia in a Phase 3 clinical trial, and SLS009, a highly selective CDK9 inhibitor currently in Phase 2 trials.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLS","symbol_name":"SELLAS Life Sciences Group Inc.","start_time":0,"source_url":"","article_id":"1113865065","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113865065","pubTimestamp":1789379635,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 14, SELLAS Life Sciences Group Inc. fell 8.19% in pre-market trading, trading at $10.70 USD/share, with turnover of $438,600. The stock had already declined 14.42% in the prior trading...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLS":"SELLAS Life Sciences Group Inc."},"translate_title":"走势警报|SELLAS Life Sciences Group Inc. 在盘前交易中下跌 8.19%，交易价格为 10.7 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":1},"content_text":"On September 14, SELLAS Life Sciences Group Inc. fell 8.19% in pre-market trading, trading at $10.70 USD/share, with turnover of $438,600. The stock had already declined 14.42% in the prior trading session, extending a sharp short-term downtrend.Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, individual stock performance was mixed. Among major names, Amgen up 1.08%, AbbVie up 0.61%, Gilead Sciences up 0.41%, Vertex Pharmaceuticals down 0.06%, Moderna down 0.78%.SELLAS Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidates include galinpepimut-S (GPS), targeting acute myeloid leukemia in a Phase 3 clinical trial, and SLS009, a highly selective CDK9 inhibitor currently in Phase 2 trials.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}